Masitinib for Multiple Sclerosis-Phase IIB/III trial results
3,971
Published 2021-01-27
Selected sources:
2012 masitinib progressive MS pilot study: bmcneurol.biomedcentral.com/articles/10.1186/1471-…
Review of emerging MS therapeutics: www.ncbi.nlm.nih.gov/pmc/articles/PMC4720678/
The role of mast cells on the blood brain barrier: pubmed.ncbi.nlm.nih.gov/26004870/
AB science press release of the phase 2B/3 study on masitinib in progressive MS: www.globenewswire.com/news-release/2020/09/14/2092…
Article on the masitinib from the Barts MS blog: multiple-sclerosis-research.org/2020/09/progressiv…
Abstract from Dr. Vermersch about the phase II trial: cslide.ctimeetingtech.com/msdc2020/attendee/person…
MS news today article on masitinib: multiplesclerosisnewstoday.com/news-posts/2020/09/…
Product label of MASIVET: www.ema.europa.eu/en/documents/product-information…
Tyrosine Kinase Pathway: www.researchgate.net/figure/Schematic-representati…
Comment or ask questions below! I would be happy to answer!
Subscribe on YouTube for more videos every Wednesday!
Make video requests in the comments section!
My book "Resilience in the Face of Multiple Sclerosis" on Amazon: www.amazon.com/dp/B07WP7H5LK
Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research.
Follow me on twitter: twitter.com/Brandon_Beaber
Music: INNER GRACE - Copyright 2018 Wilton Vought Source: Really Really Free Music Link: • Video T
he video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.
All Comments (21)
-
excellent video, as per your usual! Thank you for this!
-
Thanks for breaking the evidence down for us so succinctly Dr Beaber! I'm encouraged that this could be a possibility for those of us over 60 with progressive disease. I just hope it's available soon! Otherwise I may have to go to the vet and bark like a pup! Lol!
-
Nice to see therapies that show hope for progressive forms of MS. Would be nice to have the "right to try" philosophy extended to other conditions such as MS; especially those who have advanced to EDSS 5+. Great video!
-
Thanks for the great video, giving pwMS again some hope! Best regards from Germany!
-
I'm not a specialist, only a shareholder from France but your explanation was clear and well organized, thanks for this nice video. Hope for sick people that Masitinib will be authorized soon everywhere in the world
-
Again, great video, and thanks!
-
Thank you - sharing ❤️✌🏻
-
Thank you doctor for another cool and interesting video! Is the mechanism of masitinib the same as that of evobrutinib (in this case studied for RRMS)? I think this kind of research based on the innate response of the immune system is very promising. Thank you very much for making the results understandable for us!
-
Great video hope FDA will allowed soon
-
Ok, let's combine this with ocrelizumab and let's start tomorrow. Not trying to be funny, but 2 year trial starting from?? Plus some insurance company BS probably. I might be at EDSS 7 by then. Question: Is there a reason you can think of why this might not go along with other DMT? Combining stuff might be the only hope for progressive patients. Well maybe I am not in my most positive mood today.
-
bonjour ce n'est pas possible d'avoir la traduction.... tout le monde n'a pas la chance de parler anglais merci
-
Hey Brandon. Would you care to elaborate on what p-value means in the context of medical articles?
-
Thank you for sharing sir. I was wondering what your personal opinion is on Mavenclad.
-
Hi Dr. Beaber. Do we know the cognitive benefits of taking BTK inhibitors? We know that disability-wise is awesome, but do we have data on Cognition and Brain Volume? Thanks.
-
Seeing as though the target of this drug is completely different than that of an ocrevus or the other popular ms drugs & we see results as good as those, I would love to see a combined treatment study using this & ocrevus. Ocrevus seems to be the most effective with least side effects and risks, also reduce brain atrophy ( something which ( might be wrong ) only lemtrada and hsct show ) & has amazing 6 year results.
-
Dr. Beaber, please study the IVM (Ivermectin) drug, which deals with P2X4 receptor and has very promising remyelination properties.
-
Nice when treatments aren’t pigeon holed for singular conditions and show promise across the human playing field. I saw a promising study using proprionic acid Your thoughts?
-
Hello Dr. Brandon Beaber So if it works how long wold it take to be available from now?
-
Would this medication be in pill form if approved ? My therapy now tysabri infusions. Thankyou for another informative video.
-
Sir, as I see, there are some BTK inhibitors that are already being used to treat certain cancers in humans and this one, Masitinib, has been approved to treat mast cell tumours in dogs. It seems the company, AB Science is now trying to repurpose the same drug to treat MS.
